Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DuoCAR20.19.22-D95 in Relapsed or Refractory B-cell Malignancies
NCT06879340Phase 1Recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Mar 2025
- Primary completion
- Mar 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DuoCAR20.19.22-D95 in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma, sponsored by University of Kansas Medical Center. Primary endpoints: Maximum Tolerated Dose at 30 days, Recommended Phase 2 Dose at 30 days and 3 more. Started Mar 2025; status: recruiting.
02
Drugs
DuoCAR20.19.22-D95
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06879340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879340.